A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Southern California
University of Washington
Disc Medicine, Inc
Chengdu Zenitar Biomedical Technology Co., Ltd
Ionis Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Massachusetts General Hospital
University of Miami
M.D. Anderson Cancer Center
Icahn School of Medicine at Mount Sinai
Thomas Jefferson University
Thomas Jefferson University
PharmaEssentia Japan K.K.
Incyte Corporation
Protagonist Therapeutics, Inc.
PharmaEssentia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Roswell Park Cancer Institute
City of Hope Medical Center
RWTH Aachen University
M.D. Anderson Cancer Center
Italfarmaco
M.D. Anderson Cancer Center
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Institute of Hematology & Blood Diseases Hospital, China
Ottawa Hospital Research Institute
Protagonist Therapeutics, Inc.
Sierra Oncology LLC - a GSK company
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
Hoffmann-La Roche
Gruppo Italiano Trapianto di Midollo Osseo
Icahn School of Medicine at Mount Sinai
H. Lee Moffitt Cancer Center and Research Institute
University of Oklahoma
Kartos Therapeutics, Inc.
Sierra Oncology LLC - a GSK company
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Italfarmaco
Italfarmaco
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center